Expanded cord blood hematopoietic stem cells for hematologic malignancies

Umbilical cord blood-derived hematopoietic stem cells (HSCs) are indicated for patients with hematologic malignancies undergoing transplantation with myeloablative conditioning. The patients are treated with HSCs previously expanded ex vivo on a mesenchymal precursor cell (MPCs) feeder layer. A 100-day patient survival and sustained engraftment of both neutrophils and platelets were achieved in 80% of the treated patients.